Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia NasalCrom Expanded Use In Young Children Approved By FDA

This article was originally published in The Tan Sheet

Executive Summary

Pharmacia will use a professional detailing force to notify allergists about NasalCrom nasal spray's newly approved indication for use in children ages two to five.

You may also be interested in...



Generic cromolyn sodium

Bausch & Lomb receives FDA clearance for private label OTC nasal solution July 3. B&L's application (ANDA 75-702) appears to be first approved by agency for generic equivalent to Pharmacia's NasalCrom, which lost marketing protection July 3, 2000 after receiving six months of pediatric exclusivity. Perrigo said it will introduce a cromolyn sodium product this year. In late March, Pharmacia received approval of a new age indication for NasalCrom, allowing for use in children ages two to five (1"The Tan Sheet" April 9, p. 11)

Generic cromolyn sodium

Bausch & Lomb receives FDA clearance for private label OTC nasal solution July 3. B&L's application (ANDA 75-702) appears to be first approved by agency for generic equivalent to Pharmacia's NasalCrom, which lost marketing protection July 3, 2000 after receiving six months of pediatric exclusivity. Perrigo said it will introduce a cromolyn sodium product this year. In late March, Pharmacia received approval of a new age indication for NasalCrom, allowing for use in children ages two to five (1"The Tan Sheet" April 9, p. 11)

Generic cromolyn sodium

Bausch & Lomb receives FDA clearance for private label OTC nasal solution July 3. B&L's application (ANDA 75-702) appears to be first approved by agency for generic equivalent to Pharmacia's NasalCrom, which lost marketing protection July 3, 2000 after receiving six months of pediatric exclusivity. Perrigo said it will introduce a cromolyn sodium product this year. In late March, Pharmacia received approval of a new age indication for NasalCrom, allowing for use in children ages two to five (1"The Tan Sheet" April 9, p. 11)

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel